Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced new data showing that the deep learning capabilities of the Nucleai platform accurately analyzed and classified the spatial arrangement of immune cells in the tumor microenvironment (TME) to identify metastatic non-small cell lung cancer (mNSCLC) patients who are likely to benefit from pembrolizumab, an immune checkpoint inhibitor (ICI) therapy. This work is part of several ongoing studies examining the spatial arrangement of immune cells in the TME and the significance of this research is its potential to identify new predictive spatial immune signatures in a large-scale, multi-site patient dataset.